CapsoVision, Inc. filed a Form 10-Q with the SEC on November 12, 2026, covering the quarterly period ended September 30, 2026, disclosing financial statements and operational updates for the medical device company.

Key Highlights

  • Share count: As of November 11, 2026, CapsoVision had 53,609,719 shares of common stock, $0.001 par value per share, outstanding.
  • Listing: Common stock trades on NASDAQ:CV under the symbol CV on The Nasdaq Stock Market LLC.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Shell company status: The filing confirms CapsoVision is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Products referenced: The filing references CapsoCam Plus, CapsoCam Colon, and a CapsoCam UGI system, along with AI Highlights, as part of the company's product portfolio.
  • Regulatory activity: According to the filing, the company disclosed expected timing for submission of a 510(k) application for a second-generation CapsoCam Colon capsule and plans related to pediatric use clearance.

CapsoVision's Capsule Endoscopy Business and Q3 2026 Filing Details

CapsoVision, Inc., headquartered at 18805 Cox Avenue, Suite 250, Saratoga, CA 95070, develops and commercializes capsule endoscopy products for gastrointestinal imaging. The company's principal products, as described in the filing, include the CapsoCam Plus capsule for small bowel imaging and the CapsoCam Colon capsule, which the company disclosed is awaiting FDA 510(k) clearance. The filing also references a CapsoCam UGI system under study and an AI Highlights feature for which FDA clearance is described as pending.

According to the filing, CapsoVision confirmed it has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically. The quarterly report covers the period ended September 30, 2026, with condensed balance sheets presented as of September 30, 2026 and December 31, 2025. The company operates under Commission file number 001-42705 and is incorporated in Delaware with IRS Employer Identification Number 20-3369494.

The filing contains forward-looking statements subject to the company's cautionary language. Among the topics addressed in those statements, according to the filing, are the company's ability to continue as a going concern, anticipated use of net proceeds from equity financings including sales under an at-the-market offering program, and the potential impact of U.S. trade policies and tariffs on costs, gross margin, and supply chain. The company stated it is "under no duty to update any of these forward-looking statements after the date of this Quarterly Report."

What Was Disclosed

CapsoVision, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, reporting 53,609,719 shares of common stock outstanding as of November 11, 2026, and identifying itself as an emerging growth company listed on NASDAQ:CV.